Literature DB >> 4031015

Prolonged treatment of Cushing's disease by ketoconazole.

N Sonino, M Boscaro, G Merola, F Mantero.   

Abstract

Ketoconazole, used in clinical practice as an antifungal medication, recently was found to be a potent inhibitor of gonadal and adrenal steroidogenesis in vitro and in vivo. The effects of prolonged treatment with this agent in Cushing's disease were investigated in five patients who had recurrent severe hypercortisolism after selective transsphenoidal surgery. The patients received the drug for at least 2 months. Urinary cortisol markedly decreased in all patients immediately after the beginning of treatment with ketoconazole (800 mg/day) and remained within low normal levels when the daily dose was lowered to 600 mg/day. Plasma cortisol also decreased. After 4-6 weeks of treatment, the clinical features of the disease regressed in all patients without signs of toxicity. These findings indicate that ketoconazole may be a valuable drug for the management of patients with Cushing's disease because of its ability to correct hypercortisolism quickly.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031015     DOI: 10.1210/jcem-61-4-718

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 2.  Novel medical approaches for the treatment of Cushing's disease.

Authors:  A P Heaney
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 3.  PPAR-gamma in Cushing's disease.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

5.  Failure of long-term therapy with sodium valproate in Cushing's disease.

Authors:  A Colao; R Pivonello; F S Tripodi; F Orio; D Ferone; G Cerbone; C Di Somma; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

6.  Preoperative ketoconazole therapy for adrenocortical carcinoma.

Authors:  L J Sinnaeve; G P Becks
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 7.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

Review 8.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

10.  Inhibition of human adrenal androgen secretion by ketoconazole.

Authors:  M M Weber; P Luppa; D Engelhardt
Journal:  Klin Wochenschr       Date:  1989-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.